Chart Review of Patients Undergoing Ketamine Treatments for Depression

CompletedOBSERVATIONAL
Enrollment

250

Participants

Timeline

Start Date

April 1, 2022

Primary Completion Date

June 29, 2025

Study Completion Date

June 29, 2025

Conditions
Depression - Major Depressive Disorder
Interventions
DRUG

ketamine hydrochloride

Racemic ketamine is a 50/50 mixture of enantiomers (S)-ketamine and (R)-ketamine. The repeated administration of racemic ketamine intravenously at subanesthetic doses has emerged as an efficacious treatment for treatment-resistant depression.

Trial Locations (1)

L4Y 1M3

Ontario Ketamine and Infusion Centre - Toronto Site, Mississauga

All Listed Sponsors
lead

Sunnybrook Health Sciences Centre

OTHER